Chronic conditions and behavioural change approaches to medication adherence: rethinking clinical guidance and recommendations by Read, Simon et al.
P E R S P E C T I V E S
Chronic Conditions and Behavioural Change
Approaches to Medication Adherence: Rethinking
Clinical Guidance and Recommendations
This article was published in the following Dove Press journal:
Patient Preference and Adherence
Simon Read 1
James Morgan 2
David Gillespie 3
Claire Nollett 3
Marjorie Weiss 4
Davina Allen 1
Pippa Anderson 5
Heather Waterman 1
1School of Healthcare Sciences, Cardiff
University, Cardiff, Wales, UK; 2Cardiff
and Vale University Health Board, Cardiff,
Wales, UK; 3Centre for Trials Research,
Cardiff University, Cardiff, Wales, UK;
4School of Pharmaceutical Sciences,
Cardiff University, Cardiff, Wales, UK;
5Swansea Centre for Health Economics,
Swansea University, Swansea, Wales, UK
Abstract: Patient adherence to medication is an ongoing concern for clinicians, obfuscating
treatment efﬁcacy and resulting in wastage of medicine, reduced clinical beneﬁt, and
increased mortality. Despite this, procedural guidance on how clinicians should best engage
patients regarding their medicine-taking is limited in the United Kingdom. Adherence for
chronic conditions is notably complex, requiring clear education, communication, and
behavioural shifts to initiate and sustain daily regimens successfully. This article explores
current clinician guidance on assuring patient adherence to medication within the National
Health Service, comparing it to that provided for healthcare workers in the ﬁeld of beha-
vioural change. Outlining the inertia of the former and the progress of the latter, we consider
what steps should be taken to address this deﬁcit, including greater focus on patient concerns,
as well as knowledge translation for healthcare professionals in future adherence research.
Current United Kingdom clinical guidance for assuring patient adherence is largely outdated
based on inconclusive evidence for best practice. However, efforts to encourage behavioural
change in the public health setting demonstrate evidence-based success. Integrating knowl-
edge generated around adherence behaviour and the practical application of adherence and
behavioural change research, as well as funding for longer-term studies with a focus on
clinical outcomes, may help to solidify the NICE guidance on adherence and further progress
the ﬁeld. This would require close involvement from patient groups and networks informing
ethical aspects of study design and clinical implementation.
Keywords: adherence, chronic conditions, behavioural change, clinical guidance,
knowledge translation
Introduction
The 2003 World Health Organisation report into medication adherence highlighted
that in developed countries only around 50% of medication was taken as prescribed,
resulting in wastage of medicine, reduced clinical beneﬁt and increases in avoidable
mortality.1 In the United Kingdom, similar ﬁgures are reported with only 16% of
patients prescribed new medicine taking it as intended, experiencing no problems
and receiving as much information as they need.2 Consequently, 10 days after
starting a prescription, a third of patients are already non-adherent.2
While considerable research and policy effort has been applied to this issue,
progress towards a compelling understanding of the problem has been slow. Taking
medication for chronic conditions is widely acknowledged as a complex issue,
requiring mitigating efforts from both patients and healthcare professionals over the
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lifespan of treatment.1 However, much of the guidance
offered to clinicians on best practice is either difﬁcult to
access or limited in scope.3
As with most clinical practice guidelines across the world,
the United Kingdom’s evidence-based guidance is provided
by a centralised organisation; the National Institute for Health
and Care Excellence (NICE). The main role of NICE is to
establish balance between the beneﬁts and costs of providing
healthcare within the National Health Service (NHS) and the
wider social care setting; people’s needs for such services; and
the desirability of promoting innovation within them.4 Again,
as with similar organisations in other countries such as the
United States, the purpose of this overarching advice is to
enable a large health service comprised of numerous linked,
independent bodies to provide high-quality care. NICE also
undertakes Technology Appraisals which focus on the use of
new and existing medicines, products and treatments in the
NHS.4 However, the way clinical guidance is presented, par-
ticularly in relation to issues of medication adherence, can
limit its practical application.
The strategy provided to NHS healthcare professionals
addressing individual adherence remains relatively obli-
que, while the wider direction of adherence research and
its translation to the clinical environment is also lacking.
This article explores the existing NICE clinical guidelines
for medication adherence in chronic conditions, looking to
identify the root of these strategic deﬁcits. In doing so, we
will compare this limited guidance to that offered in the
related ﬁeld of behavioural change, where considerable
progress has been made.
Guidance on Medication Adherence
Guidance on adherence is provided through NICE docu-
mentation speciﬁcally addressing the issue (CG76), as well
as being brieﬂy referred to within condition-speciﬁc guide-
lines. Condition-speciﬁc guidelines offer limited advice
for clinicians, predominantly indicating that discussions
around patient medicine-taking should be integrated into
clinical consultations, the need for patient education, infor-
mation provision and understanding of their condition, as
well as communication and support channels. However,
precisely what these discussions should entail and the
theoretical framework inﬂuencing them remain unclear.5–7
Instead, for further detail, clinicians are largely directed
to the wider CG76 guidance on adherence. Last updated in
2009, the CG76 document theoretically frames adherence
through a binary model of intentional and unintentional
adherence issues.8 The intentional and unintentional concept
of adherence behaviour was developed to outline more com-
mon examples of how patients do not take their medication,
ﬁrst being formally proposed in 2002.9 Unintentional adher-
ence issues are deﬁned by patient passivity provoking issues
with the maintenance of their regimen. This could relate to
difﬁculties with prescription reﬁlls, inadequate understand-
ing of treatment plans, poor education, or other factors such
as physical difﬁculties in administration. However, inten-
tional adherence issues are characterised by an active patient
effort to modify or reject their treatment plan, reﬂecting
a decision-making process incorporating competing and con-
ﬂicting factors.10 This element of the adherence conundrum
has attracted most attention, with evidence suggesting that it
is inﬂuenced by a range of factors such as medication side
effects, inherent beliefs about medication or the health sys-
tem, and the patient’s perception of their condition.10
While the theoretical analysis of intentional and uninten-
tional adherence has granted amore nuanced understanding of
patient behaviour, the limitations of the approach have
become increasingly clear over the last 15 years. A major
problem is the theoretical overlap between intentional and
unintentional actions, both of which can contribute to the
same behavioural outcome. Forgetfulness, for instance,
could arise from unintentional memory issues and/or an inten-
tional motivation to deprioritise treatment.11 Furthermore, this
approach overwhelmingly stems from a psychological foun-
dation, limiting contributory social factors affecting adher-
ence. More importantly, though, this theoretical gap has
been unhelpful in identifying adherence interventions that
address these problems.
Inconclusive Evidence on
Adherence Best Practice
A recent review of 49 randomised clinical trials identiﬁed
several techniques to improve adherence.12 These include
patient education, medication regimen management, med-
ication-taking reminders, motivational interviewing to
improve cognitive behaviour, and consultations with clin-
ical pharmacists for chronic disease co-management.12
Each of these techniques has been evidentially successful
in the research setting, offering greater granularity on how
clinicians can respond to adherence issues. However,
although the NICE guidance on medicines adherence
acknowledges the existence of these techniques, the docu-
ment predominantly emphasises the inconclusiveness of
such interventions and recommends their use only when
speciﬁc needs have been identiﬁed.8
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The extent to which this problematises adherence
assessments during clinical practice is debatable. Taking
the chronic eye condition of glaucoma as an example, as
with much condition-speciﬁc guidance, NICE mention
patient education, information provision, and access to
support channels.7 However, when or how this should be
integrated into the care pathway, who is best placed to
perform such activities, and what these activities should
entail remain opaque.
This lack of an overarching view on best practice argu-
ably contributes to an absence of adherence checks within
standard care.13 Rather than attempt to address difﬁcult-to-
identify adherence issues with inconclusive interventions,
the default pathway for many clinicians may be to assume
treatment inefﬁcacy.13 Consequently, patients can often be
provided additional treatment for conditions they are strug-
gling to manage for other complex reasons.14 This also has
an economic impact for the NHS, with a recent systematic
review reporting that across 14 disease groups lower levels
of adherence were generally associated with higher treat-
ment costs. That said, the quality of these studies has been
critiqued, with few demonstrating the highest research
standards.15
Behavioural Change Guidance and
the COM-B Approach
Although their links are not formalised within NICE gui-
dance, the issues of behavioural change and medication
adherence for chronic conditions are underpinned by many
common concerns. A synthesis of qualitative research
covering patient views has concluded that many actively
resist taking medicines based on concerns over their neces-
sity and effectiveness.16 Furthermore, the complexity asso-
ciated with these responses to adherence has been shown
to emanate from a range of behavioural dimensions,
including psychological reactance.17 Patients being pre-
scribed new long-term medication require similar levels
of support, encouragement, and education to those making
other long-lasting lifestyle changes. This requirement is
greater still where conditions are asymptomatic and treat-
ments are to prevent deterioration, as with daily use of
statins for hypertension or eye drops for glaucoma.
The NICE documents on individual (PH49) and more
general (PH6) approaches to behavioural change target issues
such as dieting, encouraging physical exercise, and reducing
health-damaging behaviours.18,19 Much like adherence beha-
viours, the root of these issues is complex and variable for
different patients. Yet, these recommendations demonstrate
greater strategic direction about which individual and struc-
tural approaches may aid meaningful change in the area.
These include development of locally speciﬁc policies and
strategies, provision of training to staff, the use of proven,
evidence-based intervention techniques, and interlinkage
between national bodies, such as Royal Colleges, and local
organisations delivering interventions. Such efforts have
arguably enabled the ﬁeld of behavioural change to advance,
with long-term patient involvement and effective knowledge
translation being a key force.
The Capability, Opportunity and Motivation (COM-B)
model of behaviour20,21 is the central theoretical framework
for these NICE recommendations. The model is based on
health psychology but also accounts for structural, social,
and environmental factors, making it applicable to many
situations where behavioural change is required. Offering
greater granularity than the intentional/unintentional model
of adherence outlined in the NICE guidance, the categories
of COM-B fall into six distinct types: psychological and/or
physical capability; physical or social opportunity; reﬂec-
tive and/or automatic motivation. In relation to medication
adherence, it is proposed that physical capability could
apply to issues of dexterity that may hinder medicine-
taking, as well as ability to adapt to changes in lifestyle.22
Psychological capability, however, refers to a patient’s
understanding of their condition, as well as how their med-
ication inﬂuences it. This could also include issues of cog-
nitive impairment and memory issues.22 Physical and social
opportunity comprises access issues such as availability of
medication, packaging problems or regimen complexity, as
well as religious or social beliefs, or the stigma associated
with conditions.22 Reﬂective and automatic motivation
involve patient perception of their illness, beliefs around
its treatment and the likely clinical outcomes, as well as
education provision for patients and issues associated with
depression or changing mood states.22
Research within the ﬁeld has expanded quickly, with the
development of a comprehensive list of behaviour change
techniques weighted by their evidence-based effectiveness.19
Examples where techniques have been shown to be successful
include the use of self-monitoring in the promotion of physical
exercise or healthy eating, and goal setting for smoking
cessation22 (see Table 1 for further examples, including studies
on adherence). Gathering knowledge on factors inﬂuencing
adherence should be conducted within a similar framework
encouraging long-term patient involvement and informed,
evidence-based interventions. However, prior to this
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a systemic reconsideration of adherence is required, account-
ing for some of the behavioural, structural, and theoretical
problems outlined above.
Discussion
Healthcare professionals and researchers in the NHS are
cursorily aware of the systemic issues provoking variation
in standard care. Many health settings are busy with an
unpredictable level of case complexity limiting opportu-
nities for patient communication and interaction. In these
situations, unfamiliar and poorly deﬁned processes are
more likely to be sacriﬁced than those felt to be clinically
critical. Based on the NICE guidance for adherence where
there are limited overarching mechanisms to guide clinical
behaviour, adoption of strategies to enhance adherence
behaviour in clinic is understandably limited. Comparable
issues have been identiﬁed in the clinical practice guide-
lines of the United States, where advice on medication
adherence is similarly oblique offering “vague strategies,
with few speciﬁcs”.23 Additionally, the inconclusive evi-
dence on speciﬁc adherence interventions suggests that any
techniques clinicians in either country might deploy may
have limited effect.
Improving adherence will have health-related beneﬁts
for patients and enable better use of healthcare resources.
The linkage of available information on medication adher-
ence with theories emerging from social science,24 com-
prehensive theories of behavioural change and guidance
on speciﬁc conditions would help to improve clinician
engagement with their patients’ medicine-taking. As well
as offering a more developed model of the factors inﬂuen-
cing adherence, the growth of knowledge around interven-
tion techniques would support better-informed decisions
on those best suited for speciﬁc patients, which healthcare
professional is best placed to perform them and at what
stages they should be utilised. While individualised beha-
vioural interventions have not yet been developed, the data
gathered around those elements which work for certain
patients at certain times can foster progress in this direc-
tion. Additionally, the integration of overlapping and
related NICE documentation would also address clinician-
reported issues of information overload.25
This updating and restructuring of guidance and recom-
mendations should be carried out alongside a theoretical
and methodological rethinking of adherence itself. The
deﬁnition outlined within current NICE guidance has been
theoretically superseded. A more contemporary taxonomy
of medication adherence suggests that it should be consid-
ered over the lifespan of the prescription so that speciﬁc
issues can be addressed in a phased manner. These phases
include medication initiation, implementation, persistence,
and discontinuation (see Table 2 for deﬁnitions).26 Thus,
a patient initiating a new regimen may be more prone to
difﬁculties arising from physical opportunities such as the
availability of a prescription, or a lack of patient education.
By contrast, another patient may be more likely to encoun-
ter motivational issues persisting with their medication
much later into the prescription’s lifespan.
We recommend future research in the ﬁeld to continue
testing appropriate, evidence-based behaviour change
techniques within a theoretical framework that accounts
Table 1 Examples of Studies Using COM-B Model with Health
Behaviours
Reference Targeted Health
Behaviour
Michie S, Abraham C, Whittington C et al
(2009): Effective techniques in healthy eating
and physical activity interventions: a meta-
regression. Health Psychology, 28 (6): 690–701.
Healthy eating/
physical activity
Lorencatto F, West R, Michie S (2012):
Specifying evidence-based behavior change
techniques to aid smoking cessation in
pregnancy. Nicotine & Tobacco Research, 14 (9):
1019–1026.
Smoking
Ellis K, Pears S, Sutton S (2019): Behavioural
analysis of postnatal physical activity in the UK
according to the COM-B model: a multi-
methods study. BMJ Open, 9 (8).
Physical activity
Barker F, Atkins L, de Lusignan S (2016):
Applying the COM-B behaviour model and
behaviour change wheel to develop an
intervention to improve hearing-aid use in
adult auditory rehabilitation. International
Journal of Audiology, 55 (3): S90-S98.
Hearing aid use
Felix B, Guerreiro MP, Cavaco A et al (2019):
Development of a Complex Intervention to
Improve Adherence to Antidiabetic
Medication in Older People Using an
Anthropomorphic Virtual Assistant Software.
Frontiers of Pharmacology, 10: 680.
Medication
adherence
Herber O, Atkins L, Stork S et al (2018):
Enhancing self-care adherence in patients with
heart failure: a study protocol for developing
a theory-based behaviour change intervention
using the COM-B behaviour model (ACHIEVE
study). BMJ Open, 8 (9).
Self-care/adherence
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for factors inﬂuencing adherence. Importantly, any such
studies should recognise that these factors are likely to
vary over time and will require ongoing patient support
and education, as well as consideration as to which health-
care professionals may be best placed to provide this.
For this to succeed, data collection methods also need to
be addressed. Many adherence studies have focused on the
short-term aspects of treatment primarily because of limited
funding for longitudinal studies. Consequently, there has
been a tendency to study proxy clinical outcomes, given
that these are more easily measurable in limited time frames.
For instance, research into adherence for glaucoma eye drops
has focused on the primary outcome of eye pressure reduc-
tion rather than the prevention of vision loss and condition
severity.27 Numerous studies have embraced the initiation
and implementation phases of a newly diagnosed medicine
but have lacked the resources to track this over long-term
treatment of chronic conditions.
Observations are confounded by the poor reliability of
adherence data drawn from patient self-reporting, prescrip-
tion reﬁlls or event monitoring systems that record actions
such as the opening and closing of a pillbox, but not the
taking of the medicine. These types of data collection
closely mirror actual behaviour but remain proxy measures
that are far from ideal. Developments in technology may
enable future measures that more accurately account for
the actual administration of medicine and the resource
impact of adherence issues; the pursuit of these should
also be a key priority.
Alongside the need for more accurate measurement and
a clearer understanding of what inﬂuences variability in
adherence over time, both long-term patient involvement
and effective translation of research into healthcare profes-
sional practice are paramount. Patient choices regarding their
health and how their adherence is monitored are key to
unpicking behavioural ﬂuctuations and subsequently how
best to individually address them. Future studies looking to
examine adherence behaviours should consider patient per-
spectives in both study design and implementation, ensuring
that ethical concerns in relation to monitoring of medicine-
taking are sensitively negotiated in advance. Aside from this,
establishing adherence assessments and evidence-based
interventions within clinical consultations also requires the
buy-in of healthcare professionals. Re-emphasising and clar-
ifying the value of such interactions within NICE guidance
would be a useful step, but ensuring clinicians are able to
execute them through clearer support and advice will require
a multifaceted approach addressing the issues outlined
above.
Acknowledgments
The research leading to this article was funded by Health
and Care Research Wales.
Disclosure
The authors report no conﬂicts of interest in this work,
ﬁnancial or otherwise.
References
1. Sabaté E. Adherence to long-term therapies: evidence for action. 2003.
Available from: https://www.who.int/chp/knowledge/publications/
adherence_full_report.pdf?ua=1. Accessed November 25, 2019.
2. Picton C, Wright H. Medicines Optimisation: Helping Patients to
Make the Most of Medicines. London: Royal Pharmaceutical Society;
2013.
3. Nieuwlaat R, Wilczynski N, Navarro T, et al. Interventions for enhan-
cing medication adherence. Cochrane Database Syst Rev. 2014;11:
CD000011. doi:10.1002/14651858.CD000011.pub4
4. National Institute for Health and Care Excellence. NICE guidance.
2019. Available from: https://www.nice.org.uk/about/what-we-do/our-
programmes/nice-guidance. Accessed January 16, 2020.
5. National Institute for Health and Care Excellence. Hypertension in
adults: diagnosis and management. 2019. Available from: https://www.
nice.org.uk/guidance/ng136. Accessed January 16, 2020.
6. National Institute for Health and Care Excellence. Type 1 diabetes in
adults: diagnosis and management. 2016. Available from: https://www.
nice.org.uk/guidance/ng17/chapter/Patient-centred-care. Accessed
January 16, 2020.
7. National Institute for Health and Care Excellence. Glaucoma: diagno-
sis and management. 2017. Available from: https://www.nice.org.uk/
guidance/ng81/evidence/full-guideline-pdf-4660991389. Accessed
November 25, 2019.
8. National Institute for Health and Care Excellence. Medicines adher-
ence: involving patients in decisions about prescribed medicines and
supporting adherence. 2009. Available from: https://www.nice.org.uk/
guidance/cg76. Accessed November 25, 2019.
Table 2 Adherence Taxonomy (2012) Deﬁnitions
Adherence to medications is deﬁned as the process by which patients
take their medications as prescribed, composed of initiation,
implementation, persistence and discontinuation.
Initiation occurs when the patient takes the ﬁrst dose of
a prescribed medicine.
Implementation is the extent to which a patient’s actual dosing
corresponds to the prescribed dosing regimen, from initiation until
the last dose.
Persistence is the length of time between initiation and the last
dose, which immediately precedes discontinuation.
Discontinuation occurs when the patient stops taking their
prescribed medicine.
Note: Data from Vrijens et al. A new taxonomy for describing and deﬁning
adherence to medications. Br J Clin Pharmacol. 2012;73(5):691–705.26
Dovepress Read et al
Patient Preference and Adherence 2020:14 submit your manuscript | www.dovepress.com
DovePress
585
9. Wroe A. Intentional and unintentional nonadherence: a study of
decision making. J Behav Med. 2002;25(4):355–372. doi:10.1023/
A:1015866415552
10. Lowry K, Dudley T, Oddone E, et al. Intentional and unintentional
nonadherence to antihypertensive medication. Ann Pharmacother.
2005;39:1198–1203. doi:10.1345/aph.1E594
11. McHorney C, Spain C. Frequency of and reasons for medication
non-fulﬁllment and non-persistence among American adults with
chronic disease in 2008. Health Expect. 2010;14:307–320.
doi:10.1111/j.1369-7625.2010.00619.x
12. Kini V, Ho P. Interventions to improve medication adherence: a
review. J Am Med Assoc. 2018;320(23):2461–2473. doi:10.1001/
jama.2018.19271
13. Riekert K. Integrating regimen adherence assessment into clinical
practice. In: O’donohue W, Levensky E, editors. Promoting
Treatment Adherence: A Practical Handbook for Health Care
Providers. London: Sage; 2006:17–34.
14. Lam W, Fresco P. Medication adherence measures: an overview.
Biomed Res Int. 2015;2015:1–12. doi:10.1155/2015/217047
15. Cutler RL, Fernandez-llimos F, Frommer M, et al. Economic impact
of medication non-adherence by disease groups: a systematic review.
BMJ Open. 2018;8:e016982. doi:10.1136/bmjopen-2017-016982
16. Pound P, Britten N, Morgan M, et al. Resisting medicines: a synthesis
of qualitative studies of medicine taking. Soc Sci Med. 2005;61
(1):133–155. doi:10.1016/j.socscimed.2004.11.063
17. De las Cuevas C, De Leon J. Development and validation of the
patient’s health belief questionnaire on psychiatric treatment. Patient
Prefer Adherence. 2019;13:527–536. doi:10.2147/PPA.S201144
18. National Institute for Health and Care Excellence. Behaviour change:
individual approaches. 2014. Available from: https://www.nice.org.
uk/guidance/ph49. Accessed July 31, 2019.
19. Institute for Health and Care Excellence. Behaviour change: general
approaches. 2007. Available from: https://www.nice.org.uk/guidance/
ph6. Accessed July 31, 2019.
20. Michie S, van Stralen M, West R. The behaviour change wheel: a new
method for characterising and designing behaviour change interventions.
Implement Sci. 2011;6(42):1–11. doi:10.1186/1748-5908-6-42
21. Michie S, Richardson M, Johnston M, et al. The behaviour change
technique taxonomy (v1) of 93 hierarchically clustered techniques:
building an international consensus for the reporting of behaviour
change interventions. Ann Behav Med. 2013;46(1):81–95.
doi:10.1007/s12160-013-9486-6
22. Jackson C, Eliasson L, Barber N, et al. Applying COM-B to medica-
tion adherence: a suggested framework for research and
interventions. Eur Health Psychol. 2014;16(1):7–17.
23. Ruppar T, Dobbels F, Lewek P, et al. Systematic review of clinical
practice guidelines for the improvement of medication adherence.
Int J Behav Med. 2015;22:699–708. doi:10.1007/s12529-015-9479-x
24. May C, Eton D, Boehmer K, et al. Rethinking the patient: using
burden of treatment theory to understand the changing dynamics of
illness. BMC Health Serv Res. 2014;14:281. doi:10.1186/1472-6963-
14-281
25. Carthey J, Walker S, Deelchand V, et al. Breaking the rules: under-
standing non-compliance with policies and guidelines. Br Med J.
2011;343:d5283. doi:10.1136/bmj.d5283
26. Vrijens B, De Geest S, Hughes D, et al. A new taxonomy for
describing and deﬁning adherence to medications. Br J Clin
Pharmacol. 2012;73(5):691–705. doi:10.1111/bcp.2012.73.issue-5
27. Sleath B, Blalock S, Covert D, et al. The relationship between
glaucoma medication adherence, eye drop technique, and visual
ﬁeld defect severity. Ophthalmology. 2011;118(12):2398–2402.
doi:10.1016/j.ophtha.2011.05.013
Patient Preference and Adherence Dovepress
Publish your work in this journal
Patient Preference and Adherence is an international, peer-reviewed,
open access journal that focuses on the growing importance of
patient preference and adherence throughout the therapeutic conti-
nuum. Patient satisfaction, acceptability, quality of life, compliance,
persistence and their role in developing new therapeutic modalities
and compounds to optimize clinical outcomes for existing disease
states are major areas of interest for the journal. This journal has
been accepted for indexing on PubMed Central. The manuscript
management system is completely online and includes a very quick
and fair peer-review system, which is all easy to use. Visit http://
www.dovepress.com/testimonials.php to read real quotes from pub-
lished authors.
Submit your manuscript here: https://www.dovepress.com/patient-preference-and-adherence-journal
Read et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
Patient Preference and Adherence 2020:14586
